CoChat
Cited by 179

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

Open access
Doz, François, van Tilburg, Cornelis M, Geoerger, Birgit, Højgaard, Martin, Øra, Ingrid, Boni, Valentina, Capra, Michael, Chisholm, Julia, Chung, Hyun Cheol, DuBois, Steven G, Gallego-Melcon, Soledad, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Hong, David S, Italiano, Antoine, Kang, Hyoung Jin, Nysom, Karsten, Thorwarth, Anne, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Gavrilovic, Igor T, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, Drilon, Alexander, Perreault, Sebastien · 2022 · Neuro-Oncology

Abstract

Background: Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors. Methods: Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR). Results: As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3–79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16–49) for all patients. The 24-week disease control rate was 73% (95% CI: 54–87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45–100), 56% (95% CI: 38–74), and 85% (95% CI: 71–99), respectively. Median time to response was 1.9 months (range 1.0–3.8 months). Duration of treatment ranged from 1.2–31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3–4 in 3 patients. No new safety signals were identified. Conclusions: In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noab274

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 179

Metadata

Authors
Doz, F., van Tilburg, C. M., Geoerger, B., Højgaard, M., Øra, I., Boni, V., Capra, M., Chisholm, J., Chung, H. C., DuBois, S. G., Gallego-Melcon, S., Gerber, N. U., Goto, H., Grilley-Olson, J. E., Hansford, J. R., Hong, D. S., Italiano, A., Kang, H. J., Nysom, K., Thorwarth, A., Stefanowicz, J., Tahara, M., Ziegler, D. S., Gavrilovic, I. T., Norenberg, R., Dima, L., De La Cuesta, E., Laetsch, T. W., Drilon, A., & Perreault, S.
Venue
Neuro-Oncology
Published
2021-11-27
Volume
24
Issue
6
Pages
997-1007
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W3215197047
Cited by
179
References
7
FWCI
12.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. https://app.cochat.ai/papers/10.1093/neuonc/noab274
The paper
Doz, F., van Tilburg, C. M., Geoerger, B., Højgaard, M., Øra, I., Boni, V., Capra, M., Chisholm, J., Chung, H. C., DuBois, S. G., Gallego-Melcon, S., Gerber, N. U., Goto, H., Grilley-Olson, J. E., Hansford, J. R., Hong, D. S., Italiano, A., Kang, H. J., Nysom, K., . . . Perreault, S. (2022). Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/noab274

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.